RE:RE:F8I would this so but from what I understand it could already be used in a P2/3 trial. The patent situation would be better for sure since the F4 has been over since last august I think. The lipy indication is so insignificant that it has'nt drawn generics yet. I think they waited to file F8 until the latest possible date because the patent life of F8 starts from that approval date, if the case. Anyway many knoledgeable voices state that Nash is dead from our perspective because good oral drugs are coming to market soon thanks to Madrigal and others. It leaves Th1902 and it's binary outcome.